Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data. Bloomgren G, Sperling B, Cushing K, Wenten M Ther Clin Risk Manag. 2012; 8:313-321. Epub 2012 Jun 20. PMID: 22767995. Abstract CommentRecommendBookmarkWatch